## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	•	Williams, et al.	)	
Ser. No.	:	09/529,053	)	I hereby certify that this paper is being deposited with the United States Postal
Filed	:	April 6, 2000	)	Service as first class mail, postage prepaid, in an envelope addressed to:  Commissioner for Patents, P.O. Box
For	:	Anti-Viral Uses of Leflunomide Products	) ) )	1450, Alexandria, Virginia 22313-1450 on this date:  June 26, 2003
Art Unit	:	1617	) )	// // // // //
Examiner	:	S. Wang		Michael F. Borun, Reg. No. 25,447 Attorney for Applicants

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, the documents identified on the enclosed form PTO-1449, copies of which are enclosed, are disclosed to the Examiner for consideration in connection with the present application.

Applicants respectfully request acknowledgement of references A1-A4 and C6-C26, which were submitted to the U.S. Patent and Trademark Office on July 26, 2002 (copy enclosed).

Pursuant to 37 C.F.R. §1.97(c), Applicants submit the enclosed documents referred to on the enclosed PTO-1449 form as C27-C52.

A check in the amount of \$180.00 is enclosed. The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855.

A copy of this Information Disclosure Statement is attached. The submission of the documents identified on the enclosed PTO-1449 form is not an admission that they are prior art or relevant to the invention.

Respectfully submitted,

MARSHALL, GERSJEIN & BURUN

By:

Date: June 2B 2003

Michael F. Borun Registration No. 25,447

6300 Sears Tower 233 South Wacker Drive

Chicago, Illinois 60606-6357

(312) 474-6300